Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,035 matching trials from the live ClinicalTrials.gov search.
Completed No phase listed Observational

A Study of Patients With AIDS Syndrome

NCT00001120
Conditions
Sarcoma, Kaposi, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, AIDS-Related
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Menlo Park, California • San Francisco, California • San Rafael, California + 15 more
Conditions
Advanced Cancers
Interventions
Atorvastatin, Fish Oil Supplement, Placebo
Drug · Dietary Supplement · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib mesylate
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • Santa Monica, California • Washington D.C., District of Columbia + 9 more
Conditions
AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
Interventions
Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 4 more
Conditions
Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
tanespimycin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Leiomyosarcoma
Interventions
Trabectedin
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Ovarian Cancer
Interventions
carboplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 120 Years · Female only
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
144
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 112 more
Conditions
Sarcoma, Soft Tissue
Interventions
ifosfamide and doxorubicin vs gemcitabine and docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
10 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma, Osteoblastic Osteosarcoma, Recurrent Osteosarcoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
10 Years to 20 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Monrovia, California
Conditions
Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer
Interventions
Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Tucson, Arizona • Duarte, California • Denver, Colorado + 13 more
Conditions
Advanced Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma
Interventions
FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine, Cyclophosphamide, Echocardiography Test, Multigated Acquisition Scan, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Biopsy Procedure
Biological · Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2044
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Pancreatic Ductal Adenocarcinoma, Sarcoma
Interventions
Decitabine, Gemcitabine
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Phase 2 Interventional

Extension of Study ZPV-200

NCT01631903
Conditions
Uterine Fibroids
Interventions
telepristone acetate 12 mg, telepristone acetate 3 mg, telepristone acetate 6 mg, telepristone acetate 24 mg
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 47 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Miami Gardens, Florida • Houston, Texas
Conditions
Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue Sarcoma
Interventions
Zanzalintinib, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Kaposi's Sarcoma
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Solid Tumor, Lymphoma
Interventions
oral belinostat
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas
Conditions
Soft Tissue Sarcoma (STS)
Interventions
5-ALA
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Retinal Hemangioblastoma, Von Hippel-Lindau Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
7 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Soft Tissue Sarcoma, Mesothelioma
Interventions
Azacitidine, Temozolomide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Sarcoma
Interventions
epirubicin hydrochloride, ifosfamide, sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, hypofractionated radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
15 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

NCT00243685
Conditions
Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Soft Tissue
Interventions
Laboratory Assay, Mick Assay
Other
Lead sponsor
Pierian Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee • San Antonio, Texas
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Endometrial Carcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Aerobic Exercise, Biospecimen Collection, Dietary Intervention, Discussion, Goal Setting, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Resistance Training, Smartphone Application-based Intervention, Supportive Care, Tailored Intervention
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Ivosidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Conditions
Deep Fibromatosis/Desmoid Tumor, Familial Adenomatous Polyposis
Interventions
F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee